Vectura triggers new $3m milestone payment for VR315 therapy
1st Oct 2015 07:30
(ShareCast News) - Medical research company Vectura Group said it has triggered another $3m (£1.98m) milestone payment for its VR315 treatment. Vectura, which specialises in the development of products for the treatment of airways-related diseases, said it had already earned $9m (£6m) from the deal
Read moreVectura confident after successful regulatory meeting for asthma drug
28th Jul 2015 11:05
(ShareCast News) - Drug company Vectura was upbeat on the development of its VR647 asthma drug following a meeting with the US Food and Drug Administration. Shares in the stock rose 0.28% to 176.70p on the news the FDA approved Vectura's pathway to producing the medication, which is specialised for
Read moreVectura appoints AstraZeneca executive James Ward-Lilley as CEO
24th Jun 2015 07:30
Respiratory drugs specialist Vectura said on Wednesday that it has appointed James Ward-Lilley as chief executive officer and director effective 1 October. He will succeed Dr Chris Blackwell, who as previously announced, leaves the company at the end of this month. Ward-Lilley joins the group from
Read moreThursday broker round-up
21st May 2015 13:01
Barclays: JP Morgan Cazenove reiterates overweight and 285p target. StanChart: Goldman sachs reiterates neutral. St.James Place: Numis reiterates add and 1050p target. Hargreaves Lansdown: JP Morgan Cazenove reiterates neutral and raises target to 1,100p from 1,050p. UK Mail Group: RBC Capital re
Read moreeg solutions Chief trades in 1.21m shares
2nd Jul 2014 16:11
Elizabeth Gooch, the acting Chief Executive Officer of eg solutions has traded in a total of 1.21m shares at 52p each, the software company said on Wednesday. Of these, 120,000 were acquired by the company's former Chairman, Rodney Baker-Bates, and a further 60,000 by Mark Brady, a non-executive d
Read moreSector movers: Shire soars as M&A fever boosts pharma, health stocks
20th Jun 2014 13:56
News that Shire has rejected a £27bn approach by AbbVie sent shares in the pharmaceutical and healthcare equipment sectors higher on Friday as yet more M&A continued to give sentiment a boost. "A bit of M&A excitement has been just the ticket to enliven trading on what may otherwise have been somet
Read moreHasard Global founder acquires shares worth £1.8m
30th May 2014 16:15
The Non-Executive Chairman and founder of Hansard Global, Dr Leonard Polonsky, has increased his stake in the specialist long-term savings provider with the purchase of two million shares. Taking his stake in the group to 41.34%, Polonsky spent 90p a share at a total trade value of £1.8m. The de
Read moreFriday broker round-up UPDATE
30th May 2014 09:14
ASOS: N+1 Singer reduces target price from 5300p to 4100p, while staying with its hold recommendation. Cairn Energy: JP Morgan cuts target price from 315p to 279p and maintains an overweight rating. Cobham: Canaccord Genuity increases target price from 285p to 320p and reiterates a hold recommenda
Read moreVectura revenues ahead of forecasts
21st May 2014 12:19
Pulmonary drug delivery company Vectura released encouraging results after a transformational year, with revenues ahead of expectations thanks to growing royalty income. The Wiltshire company reached positive earnings before interest, tax, depreciation and amortisation (EBITDA) of £5.2m in the year
Read moreWednesday broker round-up UPDATE
21st May 2014 08:36
African Minerals: Citi reduces target price from 260p to 190p, while leaving its buy recommendation unchanged. Alliance Pharma: Numis lowers target price from 39p to 37p and maintains an add rating. APR Energy: JP Morgan shifts target price from 1082p to 1089p keeping its overweight rating. Astra
Read moreVectura Group to begin European study for asthma treatment
11th Apr 2014 14:43
Vectura Group will begin a study in Europe later this calendar year for Favolir, its investigational product for severe, uncontrolled asthma. This group said the decision underlines the company's planned strategy for a broad European development programme for Favolir, rather than a country-specific
Read moreWednesday broker round-up UPDATE
9th Apr 2014 09:09
Aberdeen Asset Management: RBC Capital moves target price from 485p to 495p and maintains an outperform rating. African Barrick Gold: Deutsche Bank upgrades to buy with a target price of 310p. African Minerals: Investec reduces target price from 241p to 198p and leaves its buy recommendation uncha
Read moreThursday broker round-up UPDATE
20th Mar 2014 09:19
Antofagasta: Deutsche Bank cuts target price from 770p to 735p and downgrades to sell. Investec cuts target price from 753p to 726p keeping its sell recommendation. Ashmore Group: HSBC Holdings lowers target price from 410p to 400p retaining its overweight rating. Avacta Group: Numis shifts target
Read moreVectura acquires German drug technology business, announces fundraising
13th Mar 2014 08:32
Vectura Group has announced the acquisition of Activaero, a German pharmaceutical technology company focused on respiratory diseases, and a fundraising to develop Activaero's lead product. The €130m (£108m) purchase, which will be funded through a combination of existing cash and equity, is expecte
Read moreSector movers: AstraZeneca, Shire lift pharma stocks on upbeat guidance
14th Jan 2014 15:22
Decent gains from AstraZeneca and Shire gave the pharmaceuticals sector a boost on Tuesday as both firms gave confident outlooks. At the JP Morgan Healthcare Conference in San Francisco, AstraZeneca Chief Executive Pascal Soriot said he expects the company to return to growth sooner than analysts c
Read more